论文部分内容阅读
作者从1973年1月至1978年底对Ⅳ期胃癌非根治性切除33例,未切除34例患者进行了治疗。方法:非根治切除组用MFCⅣ法及MF-OK432疗法,以非化疗组作为对照;未切除组用化疗同上,以单用MMC 为对照。MFC(MMC 0.08mg/kg;5Fu 10mg/kg;CTX0.8mg/kg,开始每周二次,二周后改每周一次静注共用10次);MF-O(MMC.5Fu 用法及次数同上。OK-432 0.5-1.0K.E 肌注每日一次或二日一次)。对75岁以上为了减轻骨髓抑制MMC 及5Fu 量减半。除术后一个月内死亡者外,用作判定效果的非根治切除31例、未切除27例。结果如下:
From January 1973 to the end of 1978, the authors treated 33 cases of non-radical resection of stage IV gastric cancer and 34 cases without resection. Methods: The non-radical resection group was treated with MFCIV and MF-OK432. The non-chemotherapy group was used as the control group. The unresected group was treated with chemotherapy as above, and the MMC alone was used as the control group. MFC (MMC 0.08mg/kg; 5Fu 10mg/kg; CTX0.8mg/kg, started twice weekly, changed to intravenous injection once a week for two weeks); MF-O (MMC.5Fu usage and frequency are the same as above. OK-432 0.5-1.0KE intramuscular injection once or once every two days). The amount of MMC and 5Fu over 75 years old in order to reduce myelosuppression was halved. Except for those who died within one month after surgery, 31 cases of non-radical resection and 27 cases without resection were used as determination effects. The result is as follows: